· 个股论点
相关概念： CPO 共封装光学光子学 Photonics
@I_Am_Bloateds 我仍然持有这两家公司的头寸？我持有的标的不应影响你自己的决策。 Transformer（变压器）瓶颈目前正阻碍美国AI基础设施建设，干式和液式（后者情况更极端）的交货期都非常长。$HPS.A 的积压订单同比增长96.9%，鉴于其市场份额…… 我不认为它们会消失。 我很确定我在~170时分享过这个观点，它曾翻倍，但现在回调至240，不过每个人的成本平均价不同吧。 这家比利时公司主要是2028年上半年的CPO（共封装光学）/光子量产受益者。他们与IMEC合作进行的MTP工作，以$NVDA为终端用户处于评估阶段，应该非常有趣。 他们的CHIPS法案MEMS/光子设施也将于2028年下半年投产，800V转换明年应为任何碳化硅(SiC)相关业务带来实质性收入增长。 我亏损-31%，因为我的成本平均价高得多。但它们正接近替换账面价值远高于市值的水平。
@I_Am_Bloateds I still have positions in both companies? What I hold shouldn't affect your own decisions. Transformer bottlenecks are stalling the US AI buildout now and lead times are very long for both dry and liquid (which is more extreme). Backlog is +96.9% Y/Y for $HPS.A and given their market share... I don't they're going anywhere. Pretty sure I shared this idea at ~170, it did 2x, but corrected back to 240 now, but cost average is different per person I guess. The Belgian company is primarily H1 2028 as a CPO/photonics volume ramp beneficary. And the work they're doing with MTP with IMEC for $NVDA as an end user in evaluation stage should be very interesting. Their CHIP act facility for MEMS/photonics also comes online H2 2028 too, and 800V transitions should bring them material revenue growth for anything SiC adjacent next year. I'm down -31%, since my cost average is a lot higher. But they're approaching levels where replacement book value is a lot higher than MC.